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Abstract
Recombinant Mycobacterium bovis bacillus Calmette-Gue `rin (rBCG) has been explored as a vector for vaccines against HIV
because of its ability to induce long lasting humoral and cell mediated immune responses. To maximize the potential for
rBCG vaccines to induce effective immunity against HIV, various strategies are being employed to improve its ability to
prime CD8
+ T cells, which play an important role in the control of HIV infections. In this study we adopted a previously
described approach of incorporating glycolipids that activate CD1d-restricted natural killer T (NKT) cells to enhance priming
of CD8
+ T cells by rBCG strains expressing an SIV Gag antigen (rBCG-SIV gag). We found that the incorporation of the
synthetic NKT activating glycolipid a-galactosylceramide (a-GC) into rBCG-SIV gag significantly enhanced CD8
+ T cell
responses against an immunodominant Gag epitope, compared to responses primed by unmodified rBCG-SIV gag. The
abilities of structural analogues of a-GC to enhance CD8
+ T cell responses to rBCG were compared in both wild type and
partially humanized mice that express human CD1d molecules in place of mouse CD1d. These studies identified an a-GC
analogue known as 7DW8-5, which has previously been used successfully as an adjuvant in non-human primates, as a
promising compound for enhancing immunogenicity of antigens delivered by rBCG.vectors. Our findings support the
incorporation of synthetic glycolipid activators of NKT cells as a novel approach to enhance the immunogenicity of rBCG-
vectored antigens for induction of CD8
+ T cell responses. The glycolipid adjuvant 7DW8-5 may be a promising candidate for
advancing to non-human primate and human clinical studies for the development of HIV vaccines based on rBCG vectors.
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Recombinant mycobacteria have generated renewed interest in
recent years as vectors for construction of vaccines against HIV/
AIDS and other diseases. The currently used vaccine against
tuberculosis (TB) in humans, Mycobacterium bovis bacillus
Calmette-Gue `rin (BCG), has been the preferred candidate for
this purpose owing to the vast body of knowledge on its safety and
immunogenicity, and the existence of standardized protocols for its
testing and large-scale production [1]. Recombinant BCG (rBCG)
strains expressing a wide variety of pathogenic bacterial and
parasitic antigens have been investigated as candidate vaccines [2].
In fact, from the early days of HIV vaccine research, several
antigens from simian and human immunodeficiency viruses (SIV
and HIV) have been expressed in M. bovis BCG as an approach to
the development of vaccine candidates [3–7]. This approach has
been highly appealing for several reasons, including the known
immunogenicity of BCG, its well established safety profile in
humans, and the relative ease and low cost of its production and
distribution. In addition, the use of rBCG expressing SIV or HIV
antigens as a priming vaccine in heterologous prime-boost
regimens has shown promising results in preclinical studies in
murine and non-human primate models [3,8–11].
Despite the encouraging preclinical results using rBCG as a
priming vaccine, concerns remain that the existing rBCG strains
are suboptimal with regard to their ability to generate sufficiently
robust and long-lasting T cell responses. In particular, the priming
of antigen specific CD8
+ T cells against endogenous mycobacterial
or transgene encoded antigens expressed by rBCG strains has
generally been found to be of relatively low magnitude [9,12],
most likely reflecting the known immune evasion properties of
pathogenic mycobacteria that enable them to suppress the
development of effective T cell responses [13]. This has led in
recent years to a variety of approaches to improve the
immunogenicity of rBCG-based vaccines. For example, rBCG
strains engineered to express either Listeriolysin-O from Listeria
monocytogenes or perfringolysin from Clostridium perfringens have
been generated to facilitate the translocation of mycobacterial
antigens from phagosome to the cytosol, thereby improving access
to the classical MHC class I antigen processing and presentation
pathway in order to enhance CD8
+ T cell priming [14,15]. A pro-
apoptotic rBCG strain with diminished superoxide dismutase
activity has also been shown to prime T cell responses and protect
against virulent M. tuberculosis challenge in mice more efficiently
than a standard strain of BCG [16]. Thus, through genetic
modifications of BCG vectors, there exist potential routes to the
creation of highly effective new vaccines for TB, HIV and other
infectious diseases.
Recently, there has been increasing interest in harnessing the
immunomodulatory activity of natural killer T (NKT) cells to
improve the T cell responses against vaccine antigens. Natural
killer T cells are a conserved population of innate-like effectors
that recognize specific glycolipid antigens presented by the MHC
class I-like CD1d molecule. A major subset of these cells is strongly
and specifically activated by glycolipids of the a-galactosylcer-
amide (a-GC) family, which represent a potentially useful class of
adjuvants that have shown promise in preclinical studies [17].
Stimulation of NKT cells by these glycolipids results in the
production of a wide range of cytokines including IFNc and IL-
12p70, maturation of the CD8a
+ dendritic cells (DCs) in the
lymph nodes, and subsequent activation of NK and conventional
T cells [18]. This cascade of immune reactions initiated by NKT
cells in response to a-GC has been shown in mouse models to
generate innate and adaptive immunity against a wide range of
infections and tumors [17,19,20]. In addition, NKT cell activating
glycolipids have been considered as potential vaccine adjuvants
[21–25]. For example, a-GC and its synthetic analogue 7DW8-5
have been reported as effective adjuvants for DNA- or adenovirus-
based vaccines against HIV [26,27]. Similarly, a previous study
from our laboratory showed that a-GC and its C-glycoside
analogue a-C-galactosylceramide (a-C-GC) were able to enhance
immunogenicity of M. bovis BCG against mycobacterial antigens
and its protective efficacy against TB in mice [18]. In particular,
we demonstrated that mice immunized with glycolipid modified
BCG developed significantly increased antigen-specific CD8
+ T
cell priming responses.
In the present study, we examined the effects of incorporating
NKT cell activating glycolipids on CD8
+ T cell responses against
epitopes of specific viral antigens expressed by recombinant BCG
vectors. Using the adjuvant incorporation approach developed in
our earlier study, we evaluated the effects of two potent synthetic
a-GC analogues, a-C-GC and 7DW8-5, on CD8
+ T cell priming
in mice against a viral antigen expressed in recombinant BCG
(rBCG). These studies monitored responses to an immunodomi-
nant epitope of an SIV Gag antigen as a viral immunogen
expressed in rBCG, and also assessed the secondary response
following boosting with a recombinant adenovirus vaccine
expressing the homologous Gag protein. Our findings revealed
substantial augmentation of CD8
+ T cell responses and significant
dose sparing effects for the glycolipid modified rBCG vaccines,
allowing reduction in vaccine dose to levels more consistent with
subcutaneous or intradermal delivery. In addition, studies carried
out in human CD1D knock-in mice which more closely model the
NKT cell response in humans, confirmed the enhanced CD8
+ T
cell priming effects seen in wild type mice. This partially
humanized mouse model may provide a useful tool for guiding
the selection of a-GC analogues to be used in future studies of
rBCG vaccines in nonhuman primates or human subjects.
Results
Enhancement of CD8
+ T cell responses by incorporation
of a-GalCer into rBCG
In previous studies focused on the generation of responses to
endogenous mycobacterial antigens, we showed that specific CD8
+
T cell responses were significantly enhanced by incorporation of
NKT cell activating glycolipids into a standard BCG vaccine
strain [28]. To extend these findings to rBCG vectors expressing
viral antigens, we used a BCG strain engineered to express an
SIV-Gag antigen (rBCG-SIV gag). Initial studies were performed
by priming C57BL/6 mice intravenously (i.v.) with a relatively
high dose (10
7 CFU) of rBCG-SIV gag that was either unmodified
or modified by direct incorporation of the C-glycoside a-GC
analogue (a-C-GC). Subsequently, animals were bled at several
time points and peripheral blood lymphocytes (PBLs) were stained
with the H2D
b/AL11 tetramer which identifies CD8
+ T cells
specific for the immunodominant SIV Gag epitope. In several
experiments, we observed that the primary CD8
+ T cell responses
in mice receiving unmodified rBCG-SIV gag vaccine were
undetectable, whereas these responses were consistently detected
when the glycolipid modified vaccine was administered (Fig. 1A).
Although the glycolipid adjuvant clearly facilitated primary
antigen specific CD8
+ T cell responses, these were of relatively low
magnitude. Therefore, we examined the effect of boosting these
responses by administering a suboptimal dose (10
7 viral particles
(VP)) of replication incompetent recombinant adenovirus (serotype
5) expressing the full length SIV Gag protein (rAd5-SIV gag)b y
the intramuscular (i.m.) route. Levels of circulating CD8
+ T cells
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H2D
b/AL11 tetramers. Starting at day 3 after boosting, a
detectable difference in AL11 tetramer positive T cell population
was observed between mice that were primed with unmodified
and a-C-GC modified rBCG-SIV gag, reaching a significant
difference after day 14 post boosting (Fig. 1B). Only by day 14 did
AL11 specific CD8
+ T cell responses become detectable in the
mice primed with unmodified rBCG-SIV gag, although these
responses were still higher in mice primed with the glycolipid
modified rBCG-SIV gag. These results provided evidence that the
administration of a-C-GC adjuvant in direct physical association
with the priming vaccine had a favorable impact on the induction
of antigen specific CD8
+ T cell responses, resulting in a pool of
primed CD8
+ T cells that were able to respond rapidly to the
booster vaccine.
Effects of glycolipid modification on subcutaneous
priming with rBCG
We next examined whether the effects of the glycolipid
modification observed with i.v. immunization could also be seen
after subcutaneous (s.c.) priming with rBCG-SIV gag. In initial
experiments, a relatively high priming dose (5610
6 CFU) of
rBCG-SIV gag either with or without incorporation of a-C-GC
was administered s.c., followed by boosting i.m. with a suboptimal
dose (10
7 VP) of rAd5-SIV gag. This revealed a clear priming of
AL11 specific CD8
+ T cell responses with s.c. injection of the
glycolipid modified rBCG, but not with the unmodified rBCG
vaccine (data not shown). This prompted us to examine a range of
doses of rBCG for s.c. priming to determine the extent of the dose-
sparing effect that could be achieved by glycolipid modification.
Figure 1. Enhanced primary and boosted responses to SIV Gag expressed in rBCG with incorporation of NKT cell activating
glycolipids. C57BL/6 mice were primed i.v. with 10
7 CFU of M. bovis BCG, rBCG-SIV gag, or rBCG-SIV gag modified by incorporation of a-C-GC. CD8
+
T cells specific for SIV Gag in peripheral blood samples were enumerated by flow cytometry of lymphocytes stained with H2D
b/AL11 tetramers
specific for an immunodominant Gag epitope. (A) Primary responses were analyzed at 14 days after priming. Plots on left show representative profiles
of tetramer staining of CD8
+ T cells (for complete gating strategy, see supplementary Fig. S2). Graph on right shows medians and interquartile ranges
for groups of similarly immunized mice (n=5 mice per group). *P,0.05 (Kruskal-Wallis followed by Mann-Whitney test with Bonferroni correction). (B)
Secondary responses to SIV Gag in mice boosted with rAd5-SIV gag (10
7 VP i.m.) eight weeks after priming. Plots on left show representative tetramer
staining on day 7 after boosting. Graph on right shows medians and interquartile ranges at the indicated day after boosting for groups of mice (n=5
per group) primed with rBCG-SIV gag without glycolipid modification (unmodified, open bars), or with rBCG-SIV gag with incorporation of a-C-GC
(filled bars). **P,0.01 (Mann-Whitney test).
doi:10.1371/journal.pone.0108383.g001
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4,1 0
5,1 0
6 or 10
7 CFU of
a-C-GC modified or unmodified rBCG-SIV gag, followed by
boosting with rAd5-SIV gag eight weeks later. This showed that
glycolipid adjuvant incorporation into rBCG promoted a consis-
tent trend toward higher secondary CD8
+ T cell responses 14 days
after boosting with rAd5-SIV gag even at a priming dose as low as
10
5 CFU, while the unmodified rBCG required 10
7 CFU to give
comparable priming (Fig. 2A, bar graph). This suggested a 10 to
100 fold dose sparing effect on SIV Gag specific CD8
+ T cell
priming attributable to glycolipid modification of the rBCG-SIV
gag vaccine.
We also assessed the impact of rBCG dose and glycolipid
incorporation on the development of long term memory CD8
+ T
cell responses. Mice were primed with 10
4,1 0
5,1 0
6 or 10
7 CFU of
a-C-GC modified or unmodified rBCG-SIV gag, and then
boosted 8 weeks later with rAd5-SIV gag. Six months after
boosting, spleens were harvested and expression of CD44 and
CD62L was analyzed on CD8
+ cells stained with H2D
b/AL11
tetramers (Fig. 2B). No significant differences were observed
between the groups in the fraction of Gag-specific CD8
+ T cells
displaying an effector memory phenotype (CD44
+ CD62L
neg; data
not shown). However, we observed a trend toward an increase in
the fraction of central memory cells (CD44
+ CD62L
+) in animals
primed with the glycolipid modified rBCG. This rose to a level
that was statistically significant only in animals immunized with
the lowest dose (10
4 CFU) of the glycolipid modified rBCG
Figure 2. Dose-sparing effect of a-C-GC on CD8
+ T cell priming and increased expression of central memory phenotype. (A) C57BL/6
mice were immunized s.c. with varying doses of rBCG-SIV gag (10
4,1 0
5,1 0
6, and 10
7 CFU) with incorporation of a-C-GC or without glycolipid
incorporation (unmodified). All animals were boosted 8 weeks later with 10
7 VP i.m. of rAd5-SIV gag, and PBL were analyzed for AL11 tetramer
staining at day 14 post-boost. Plots on left show Gag-specific CD8
+ T cell responses in representative mice. The percentages of tetramer positive cells
are indicated in the upper right quadrants. The graph on the right shows medians and interquartile ranges for groups of 4 mice each. Open bars
indicate mice that were primed with unmodified rBCG-SIV gag, and filled bars indicate mice primed with a-C-GC modified rBCG-SIV gag. P=0.0571
between unmodified and a-C-GC rBCG-SIV gag for both 10
5 and 10
6 CFU; Kruskall-Wallis followed by Mann-Whitney test with Bonferroni correction).
(B) Long term Gag-specific CD8
+ memory T cells were analyzed for expression of CD62L and CD44 as shown on the left. The graphs on the right show
levels of central memory AL11-specific CD8
+ T cells in PBL of mice (medians and interquartile ranges for groups of 5 mice) primed s.c. with two
different doses (10
4 or 10
7 CFU) of rBCG-SIV gag that were either unmodified or modified by incorporation of a-C-GC. All animals were boosted with
10
7 VP i.m. of rAd5-SIV gag eight weeks after priming, and spleens were harvested six months later for analysis. *P,0.05 (Mann-Whitney test).
doi:10.1371/journal.pone.0108383.g002
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glycolipid a-C-GC, or s.c. with 5610
6 CFU of rBCG-SIV gag modified with a-C-GC. After 7 days, splenocytes were analyzed for expression of PD-1 on a-
GC-loaded CD1d tetramer
+ NKT cells as shown in (A), or were re-stimulated in vitro for 48 hours with a-GC for measurement of recall cytokine
responses by capture ELISA of IFN-c and IL-4 in the culture supernatant (B). Graphs show median values with interquartile ranges for groups of three
mice each. *P,0.05; NS, not significant (Kruskal-Wallis followed by Mann-Whitney test with Bonferroni correction).
doi:10.1371/journal.pone.0108383.g003
Figure 4. Enhanced Gag-specific response with incorporation of a-GC analogue 7DW8-5 into rBCG. (A) To determine the optimal
concentration of glycolipid 7DW8-5 for incorporation into rBCG-SIV gag, a range of concentrations up to 20 mg/ml were tested. Mouse bone marrow
dendritic cells were infected with mock treated or glycolipid modified rBCG-SIV gag at a multiplicity of infection of 10:1, and cultured with NKT cell
hybridoma DN32.D3. Levels of IL-2 in the culture supernatants were assayed 24 hours later by ELISA to assess glycolipid incorporation. Median values
with ranges are shown for triplicate samples. C57BL/6 mice were primed with 10
7 CFU i.v. of unmodified rBCG-SIV gag or rBCG-SIV gag incorporated
with 10 or 20 mg/ml of 7DW8-5, and analyzed for Gag-specific CD8
+ T cells by AL11 tetramer staining of PBL samples obtained 10 days after priming
(B) or 10 days after boosting (C) with 10
7 VP i.m. of rAd5-SIV gag. Values for individual mice are shown as the percentage of AL11 tetramer stained
cells in the total CD8
+ T cell fraction, and median values are indicated with interquartile ranges. *P,0.05 (Kruskal-Wallis followed by Mann-Whitney
test with Bonferroni correction).
doi:10.1371/journal.pone.0108383.g004
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term memory CD8
+ T cells was promoted by relatively low doses
of the priming immunogen when combined with incorporation of
a-C-GC as an adjuvant during priming.
Effects of glycolipid modified rBCG on NKT cell anergy
NKT cells are known to undergo anergy following a single
injection of a-GC in mice and to remain in the non-responsive
state for more than a month after being stimulated in this way
in vivo. It is thus of interest to determine whether the a-C-GC
modified BCG vaccine vector induces NKT cell anergy when
given by a standard vaccination route (i.e., subcutaneously), which
might have undesirable effects on post-vaccination immune status.
Induction of anergy in NKT cells following systemic stimulation
with a-GC has been correlated with increased surface expression
of PD-1 [29]. Therefore, we analyzed PD-1 expression on the
surface of CD1d/a-GC tetramer positive NKT cells in the spleens
of mice following s.c. administration of 5610
6 CFU of a-C-GC
modified rBCG-SIV gag. This revealed no significant induction of
PD-1, in contrast to the NKT cells in spleens of mice receiving
injections of free a-C-GC in aqueous vehicle which showed
increased expression of PD-1 (Fig. 3A). We also studied ex vivo
recall responses of NKT cells to a-GC in the spleen seven days
after administering either free glycolipids (a-GC or a-C-GC in
aqueous vehicle) or rBCG-SIV gag modified with these glycolip-
ids. Splenocytes from these mice were re-stimulated in culture with
a-GC for 48 hours, and levels of IFN-c and IL-4 were measured in
the supernatant. Cytokine secretion in response to a-GC was
intact in mice that had received the glycolipid modified rBCG
immunization. In contrast, these responses were markedly
diminished in the mice previously injected with the free
glycolipids, consistent with the induction of NKT cell anergy
(Fig. 3B). These results indicated that s.c. administration of
glycolipid modified rBCG did not induce anergy of NKT cells.
Modification of rBCG-SIV gag using an a-GC analogue
optimized for human NKT cells
The effects of a-C-GC observed in our experiments were
consistent with the previously demonstrated high potency of this
glycolipid as an activator of NKT cells in mice. However, it has
been shown that a-C-GC is less active for stimulation of human
NKT cells, and may not be an optimal choice for use as an
adjuvant in primates [30]. Recently, an a-GC analogue known as
7DW8-5 has been reported to be a potent activator of human
NKT cells that performs well as an experimental vaccine adjuvant
in nonhuman primates [31]. Similar to a-C-GC, the in vivo
cytokine response to 7DW8-5 following systemic administration in
mice reveals a bias toward strong IFN-c production with relatively
low, transient IL-4 secretion (Fig. S3) [32]. These properties have
stimulated substantial interest in the development of 7DW8-5 as
an adjuvant for human vaccination [33]. We undertook studies to
evaluate 7DW8-5 as a candidate adjuvant for rBCG vaccines, and
assessed its activities in wild type mice and in a partially
humanized human CD1d knock-in mouse model.
In initial studies with 7DW8-5, we analyzed incorporation into
live rBCG-SIV gag cultures using concentrations of the glycolipid
ranging from 5 to 20 mg/ml, and tested the ability of the modified
bacteria to stimulate an NKT cell hybridoma (Fig. 4A). We found
a dose-dependent enhancement of hybridoma responses consistent
with stable incorporation of 7DW8-5 into the live mycobacteria,
with concentrations of 10 and 20 mg/ml delivering optimal
responses. To assess the effect on priming of CD8
+ T cell
responses to the immunodominant Gag epitope, 10
7 CFU of
Figure 5. Comparison of 7DW8-5 with a-C-GC in human CD1d knock-in mice. Purified CD8
+ T cells from tdTomato-Tg/OT-I TCR-Tg mice
labeled with CFSE were transferred into recipient humanized CD1d knock-in mice that were subsequently injected s.c. with PBS (Control), rBCG-OVA,
or rBCG-OVA modified with either 7DW8-5 or a-C-GC. After 6 days, splenocytes were harvested and CFSE fluorescence of the transferred population
was determined by gating on the B220
Neg CD8
+ tdTomato
+ lymphocytes. Representative plots showing CFSE staining and dilution are shown; OVA-
specific CD8
+ T cells are enclosed in the outlined areas of the dot plots, with residual undivided cells (i.e., without CFSE dilution) in the right hand
boxes. The graph summarizes the results as the medians and interquartile ranges of the percentages of remaining undivided OVA-specific CD8
+ T
cells for groups of mice (n=5 per group). **P,0.001(Kruskal-Wallis followed by Mann-Whitney test with Bonferroni correction). These results are
representative of two separate experiments.
doi:10.1371/journal.pone.0108383.g005
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were injected i.v. into C57BL/6 mice. Levels of CD8
+ cells
staining with the H2D
b/AL11 tetramer were measured in PBL
samples ten days later. We observed enhanced priming of Gag-
specific CD8
+ T cells in mice receiving rBCG-SIV gag modified
with the higher concentrations of 7DW8-5 (Fig. 4B). To determine
if the enhanced CD8
+ T cell priming could generate improved
responses after boosting, these mice were injected with rAd5-SIV
gag (10
7 VP i.m.) six weeks after initial priming. This revealed
increased Gag-specific CD8
+ T cell responses at 10 days after
boosting in animals primed with the 7DW8-5 modified rBCG-SIV
gag (Fig. 4C). In these studies, 10 mg/ml was found to be the most
efficient concentration of 7DW8-5 for incorporation of the
glycolipid into rBCG-SIV gag, resulting in the highest mean
CD8
+ T cell responses following both priming (Fig. 4B) and
boosting (Fig. 4C).
Activity of the glycolipid adjuvant 7DW8-5 in a
humanized mouse model
A human CD1d knock-in (hCD1d-KI) mouse line has recently
been described, providing a useful partially humanized mouse
model for the assessment of NKT cell based therapeutics and
adjuvants [34]. In these mice, the coding sequence of human
CD1d has been inserted in place of the mouse gene, leading to
expression of human CD1d in a normal pattern of tissue
distribution and at levels similar to murine CD1d in wild type
mice. Compared to C57BL/6 and other standard mouse strains,
these animals develop a functional repertoire of NKT cells with
frequency and distribution much more similar to normal humans.
To determine if 7DW8-5 could serve as an effective adjuvant when
incorporated into rBCG in this humanized mouse model, we
studied CD8
+ T cell priming using an adoptive transfer system.
Naı ¨ve CD8
+ T cells were isolated from mice expressing the red
fluorescent protein tandem dimer tomato (TdT) and TCR
transgenes specific for the ovalbumin (OVA) peptide SIINFEKL.
These were labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE), and adoptively transferred into hCD1d-KI mice.
These animals then received s.c. immunization with BCG
expressing ovalbumin (rBCG-OVA) that was either unmodified
or modified with 7DW8-5 or a-C-GC. After 6 days, splenocytes
were harvested and analyzed for proliferation of OVA-specific
CD8
+ T cells by flow cytometry (Fig. 5). An increase in CD8
+ T
cell proliferation was observed with 7DW8-5 compared to a-C-
GC modified rBCG-OVA, consistent with higher activity of
7DW8-5 in this partially humanized mouse model.
Discussion
We previously demonstrated that CD8
+ T cell responses to
endogenous antigens of M. bovis BCG can be significantly
enhanced by incorporation of NKT cell activating glycolipids
such as a-GC and a-C-GC [28]. In the current study, we have
applied this approach to improving CD8
+ T cell responses to a
retroviral antigen expressed in recombinant BCG. Using an SIV
Gag protein as the model antigen and the standard Danish strain
of BCG as the live-attenuated delivery vector, we demonstrated
significant improvements in immunogenicity directed to the
specific MHC class I presented immunodominant epitope of
SIV Gag by incorporation of the NKT cell activating glycolipids
a-C-GC and 7DW8-5. This method allows for simultaneous
delivery of protein antigens and NKT cell activating ligands by
direct infection of antigen presenting cells (APCs). These include
CD8a
+ DCs, which in mice are known to be the major APC
involved in both NKT cell responses and cross-priming of
conventional CD8
+ T cells [35]. As previously shown, mycobac-
teria including BCG do not generally express strong activators of
NKT cells [36]. Our approach of directly incorporating synthetic
CD1d-presented glycolipids provides a relatively simple approach
to correcting this deficiency, thus improving the overall potential
of BCG as a vaccine delivery vector. The ability of this approach
to enhance responses of CD8
+ T cells against specific antigens of
viruses or other pathogens expressed in rBCG strains could
potentially assist a wide range of vaccine targets. For example,
relevant to the particular case of the Gag antigen used in the
current study, it is well documented that Gag specific CD8
+ T cell
responses are strongly associated with natural control of HIV
infection in humans and with control of viral set point in
experimental SIV infection in macaques [37].
Although the levels of circulating CD8
+ T cells specific for the
immunodominant SIV Gag AL11 epitope using glycolipid
modified rBCG-SIV gag were relatively low after priming, these
responses showed robust and rapid expansion following boosting
with a sub-maximal dose of nonreplicating adenovirus expressing
the homologous SIV Gag antigen. The accelerated secondary
response observed in mice primed with adjuvanted vaccines in this
prime-boost model suggests that the CD8
+ T cells generated by
this regimen may have properties that reduce the delay in the
response of HIV-specific central memory CD8
+ T cells upon
exposure to the virus. This acceleration of the response could help
to overcome the kinetic mismatch between viral replication and
the generation of effective immune control, which may be partly
responsible for the failure to clear infection by viruses that attack
the immune system directly such as SIV or HIV [38].
Furthermore, with incorporation of the potent Th1-biasing a-C-
GC glycolipid, the immune enhancing role of the adjuvant on the
secondary response was retained when the priming vaccine was
delivered subcutaneously. Using this route of vaccination, the
incorporation of the glycolipid adjuvant gave a 10- to 100-fold
dose-sparing effect. This may assist the development of vaccination
regimens that minimize local or systemic adverse effects without
compromising immunogenicity. It should be noted that our
analyses have so far focused only on the effects of glycolipid
modification of rBCG on CD8
+ T cell responses in blood and
spleen. Further studies will be needed to determine how this
approach influences T cell responses in other relevant tissues such
as lymph nodes and various mucosal sites.
It is noteworthy that early phase clinical studies have shown that
i.v. injection of a-GC causes rapid immune activation in humans
without significant toxicity [39,40]. However, one potential
problem with a-GC that has been frequently observed in mouse
models is its property of inducing long-term anergy of NKT cells,
lasting for a month or more after systemic administration of a-GC
[41,42]. This results in the NKT cells being unresponsive to a
second stimulation with a-GC either in vivo or in vitro, creating a
prolonged host immune defect. However, when administered in
physical association with rBCG, we observed no evidence of
systemic anergy or unresponsiveness of NKT cells. Thus, splenic
NKT cells from mice injected with a-C-GC modified rBCG-SIV
gag seven days earlier were reactive to a-GC re-stimulation
in vitro. We have not yet established how this approach avoids the
problem of NKT cell anergy, although one possibility is that
association with the bacilli restricts delivery of the glycolipid to
antigen presenting cells that are incapable of inducing anergy.
Whatever the mechanism, this feature of the response to glycolipid
modified rBCG raises the possibility of regimens involving the
repeated use of NKT cell activators for both priming and boosting
of responses.
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different applications has been an important theme of recent work
in the field of NKT cell-based therapeutics [43]. Although
modification of rBCG with a-C-GC was potent in augmenting
Gag-specific CD8
+ T cell responses in wild type mice, this
synthetic glycolipid has been found to be less active for stimulation
of human NKT cells and may not be optimal for clinical
translation into humans [30,44]. Recent work has identified other
NKT cell activators, in particular the a-GC analogue 7DW8-5, as
more promising agents for development as human vaccine
adjuvants or immunomodulators [27,31,33]. Although we have
not developed methods for directly quantifying the amount of a-C-
GC or 7DW8-5 that are incorporated into rBCG, based on
previous work we anticipate that approximately 20–30% of the
glycolipid added to growing cultures becomes stably associated
with the bacilli [28]. In comparisons of a-C-GC and 7DW8-5
directly for modification of rBCG, we observed that the former
was more potent for eliciting Gag-specific CD8
+ T cell responses
in wild type mice. However, in hCD1d-KI mice, in which
presentation occurs through human CD1d only, 7DW8-5 showed
superior adjuvant effects in our rBCG priming model. This is
consistent with published findings on 7DW8-5, which showed it to
be among the most active a-GC analogues tested in non-human
primates and in cell culture with human cell lines [27]. Both a-C-
GC and 7DW8-5 have been described to stimulate a Th1-biased
immune response in mice [27,45,46], which is a quality that is
generally associated with improved CD8
+ T cell cross priming
[43].
In summary, we have shown in this study that incorporation of
NKT cell activating glycolipids provides adjuvant effects that
facilitate stronger CD8
+ T cell responses against a viral antigen
expressed in rBCG. Although SIV Gag has been used as a
convenient model antigen for these studies, this antigen and its
homologue in HIV are known to be important targets for virus
specific CD8
+ T cell responses that suppress circulating viral levels
and slow disease progression [37]. Thus, direct clinical applica-
tions can be envisioned for glycolipid modified rBCG strains as
vaccines for simultaneously stimulating beneficial immunity
against both tuberculosis and HIV. This approach should be
applicable for enhancing antigen specific CD8
+ T cell responses to
live attenuated rBCG vaccine vectors expressing a wide variety of
antigens, including other antigens of HIV or expressed by other
relevant pathogens. We conclude that the NKT cell based
adjuvant, in addition to enhancing immunogenicity of the rBCG
vector, provides significant practical advantages as it enables
significant reduction in the priming vaccine dose, and improves
responses following vaccination by a clinically feasible route. Since
rBCG strains can be constructed and produced with relative ease
and low cost, this approach to improving their immunogenicity
has potential applications for novel vaccines against a range of
infectious diseases.
Materials and Methods
Antibodies and staining reagents
Antibodies for murine IL-2, IFNc and IL-4 capture ELISA
were purchased from BD Biosciences. Antibodies used for flow
cytometry (all from BD Biosciences) included anti-mouse CD45R/
B220-PerCP, anti-mouse CD45R/B220-FITC, anti-mouse CD3-
FITC, anti-mouse CD3-V500, anti-mouse CD8a-APC, anti-
mouse CD8a-Pacific Blue, anti-mouse CD44-FITC,anti-mouse
CD62L-APC, and anti-mouse PD1-PE. BluVid viability dye
(Invitrogen) was used for live/dead staining. The APC-conjugated
a-GC loaded mCD1d tetramer and PE-conjugated AL11/H2D
b
tetramer specific for the SIV Gag immunodominant epitope
(AAVKNWMTQTL) were obtained from the NIH Tetramer
Core Facility.
Preparation of cell suspensions and flow cytometry
To obtain peripheral blood lymphocytes (PBL), approximately
300 ml of blood was obtained by retro-orbital plexus puncture and
collected into 2 ml of RPMI-1640 containing 10 U/ml of heparin
(Sigma). Samples were centrifuged at 6506g for 10 minutes at
4uC, supernatants were aspirated and 2 ml of red blood cell lysing
buffer (Sigma) was added. After 2 minutes at room temperature,
10 ml of PBS was added, and cells were collected by centrifugation
and resuspended in FACS staining buffer (PBS+2% FCS and
0.05% NaN3) for staining with fluorochrome labeled antibodies
and tetramer reagents. Spleens were collected aseptically, homog-
enized in 10 ml of RPMI-1640, and treated with red blood cell
lysing buffer similar as for blood samples except that 40 ml of PBS
was used for washing and removal of the red blood cell lysing
buffer. PBL were dispensed into wells of 96-well round bottom
plates (Corning), washed once with PBS, and live/dead staining
was performed with the Blue Live/Dead kit (Invitrogen) in PBS on
ice for 20 minutes according to the manufacturer’s instructions.
The cells were pelleted at 6506g for 2 minutes at 4uC and washed
with PBS. Samples were then incubated with the specific
fluorochrome labeled antibodies or tetramers of interest, along
with the FccRII/III blocking antibody 2.4G2 in FACS buffer
(PBS, 2% FBS, 0.05% sodium azide) for 20 minutes at room
temperature. Flow cytometry analysis was carried out using
FACSCalibur and LSR II flow cytometers (BD Biosciences), and
data were analyzed using FlowJo software (Treestar).
Recombinant BCG and adenovirus strains
The recombinant BCG strain expressing ovalbumin (BCG-
OVA) has been described previously [28]. Mycobacterium bovis
BCG Danish 1331 (Statens Serum Institute) was used for
construction of rBCG expressing SIV Gag, which will be described
in detail elsewhere (S. Lee, et al., manuscript in preparation).
Briefly, the full-length coding sequence of the gag gene of SIV
strain Mac239 was amplified by standard RT-PCR. This was
ligated into the non-integrating mycobacterial expression plasmid
pSL7 (S.L. and W.R.J., unpublished), in which the gag sequence
was fused to the M. tuberculosis hsp60 gene promoter and
upstream translation initiation site of the M. tuberculosis 19 kDa
lipoprotein gene (LpqH, Rv3763). Transformants of BCG were
selected using 50 mg/ml apramycin, cloned by selection of isolated
colonies and screened for expression of the full length SIV Gag
protein by Western blotting. Recombinant BCG strains were
grown in Middlebrook 7H9 media (Becton Dickinson) supple-
mented with 0.05% tyloxapol (Sigma) and 10% oleic albumin
dextrose catalase enrichment (OADC) (Becton Dickinson). Media
were supplemented with 50 mg/ml apramycin for rBCG-SIV gag,
or with 50 mg/ml kanamycin (Sigma) for BCG-OVA. The
recombinant adenovirus expressing Mac239 SIV gag (rAd5-
SIVgag, generously provided by Dr. Jason Gall, GenVec,
Gaithersburg, MD) was constructed in a serotype 5 virus with
deletions in the E1 and E3 regions to render it replication
incompetent [47]. Methods used for production of adenoviral
stocks and determination of viral particle (VP) titers have been
previously described [47,48].
Incorporation of glycolipids into rBCG
The glycolipids a-GC, a-C-GC and 7DW8-5 were synthesized
as previously described [27,49,50]. The chemical structures of
these glycolipids are shown in Fig. S1. Incorporation of the
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approach [28] with minor modifications. The bacteria were grown
to mid-log phase (OD600 of 0.6), harvested and washed with PBS
(Life Technologies) containing 0.05% tyloxapol (Sigma). The
bacterial pellet was resuspended and diluted in 7H9 medium
without OADC to give an OD600 of 3.0 (,9610
8 CFU/ml).
Glycolipids were suspended at 10X the desired final concentra-
tions in 7H9 medium containing 20% DMSO and 0.5%
tyloxapol. To suspend the glycolipids in this aqueous medium,
solutions were sonicated for 5 minutes in a bath sonicator
(Branson), followed by mixing for 1 minute in a vortex mixer
and heating to 80uC for 2 minutes. The bacterial suspension was
combined with an equal volume of glycolipid suspension, and this
was then diluted tenfold with 7H9 medium to give a BCG
suspension with OD600 of ,0.3, with 2% DMSO, 0.05%
tyloxapol and the desired final concentration of glycolipid (i.e.,
ranging from 0 up to 20 mg/ml, as indicated). The cultures were
then grown for 48 hours at 37uC with shaking to mid-log phase
(OD600=,0.6). Bacteria were harvested and washed twice with
10 ml of PBS+0.05% tyloxapol, followed by resuspension in PBS+
0.05% tyloxapol to the desired concentration. Mouse immuniza-
tions were done using the indicated number of CFU of glycolipid
modified bacteria in a volume of 0.1 ml, and CFU numbers were
calculated based on OD600 values with a value of 1 equal to
3610
8 CFU/ml.
Mammalian cell culture and in vitro infections
Murine cells were cultured in at 37uC in a 5% CO2 incubator in
RPMI-1640 medium supplemented with 0.8 mM L-glutamine,
10 mM HEPES, 50 mM 2-mercaptoethanol (all from Life
Technologies), and 10% fetal calf serum (Gemini). Murine bone
marrow-derived dendritic cells (BMDCs) from 6–8 weeks old
female C57BL/6 mice (Jackson Laboratories) were generated and
cultured as described previously [51]. The murine iNKT
hybridomas DN3A4-1.2 and DN32.D3 (both expressing Va14
and Vb8.2 TCR chains) were provided by M. Kronenberg (La
Jolla Institute for Allergy and Immunology, San Diego, CA) and
A. Bendelac (University of Chicago, IL), respectively. BMDCs at a
density of 1610
5 cells per well in 96 well flat bottom tissue culture
plates were infected with BCG strains with or without glycolipid
incorporation at the indicated multiplicity of infection (MOI) as
previously described [28]. Briefly, BMDCs overlayed with bacteria
were centrifuged at 4006g for 10 minutes at 4uC to initiate
infection. The infection was continued for 2 hours at 37uC and
extracellular bacteria were removed by washing the BMDCs twice
with warm complete RPMI media. The infected BMDCs were co-
cultured with 5610
4 cells per well of iNKT hybridoma for 24
hours at 37uC. Supernatants were collected and assayed for IL-2
by sandwich ELISA.
Mice and immunization
Six to eight weeks old female C57BL/6 mice (Jackson
Laboratories) were purchased and allowed to adapt to local
conditions for a minimum of 1 week prior to use in experiments.
Human CD1d knock-in mice have been recently described [34],
and were maintained in a breeding colony in our facility and used
at 6–8 weeks of age. All mice were housed and maintained in
specific pathogen-free conditions in compliance with procedures
and regulations approved by the Institute for Animal Studies and
Biosafety Committee of the Albert Einstein College of Medicine.
This study was specifically approved by the Albert Einstein
College of Medicine Institutional Animal Care and Use Commit-
tee (IACUC). Mice were primed with either unmodified or
glycolipid modified rBCG-SIV gag i.v. via tail vein or s.c. in the
flank region with the indicated bacterial doses diluted in PBS with
0.05% tyloxapol to a final volume of 100 ml. Boosting was done 8
weeks after priming with 10
7 VP of rAd5-SIV gag in 100 mlo f
PBS injected i.m. route in the quadriceps muscles (50 ml per leg).
At the indicated days post boosting, mice were anesthetized to
obtain samples of peripheral blood (for time-course measure-
ments), or were sacrificed for removal of spleens.
Analysis of NKT cell anergy
To determine if glycolipid adjuvant induced NKT cell anergy
when administered with recombinant BCG, C57BL/6 mice were
injected s.c. with 5610
6 CFU of the glycolipid modified rBCG-
SIV gag or intraperitoneally (i.p.) with 4 mg of either a-GC or a-
C-GC. Seven days later, splenocytes obtained from these mice
were analyzed ex vivo for recall responses of NKT cells by
stimulating 5610
5 cells with 100 nM a-GC in 96-well plates for 48
hours, and supernatants were assayed for IFN-c and IL-4 by
sandwich ELISA. Splenic NKT cells, identified by staining with a-
GC loaded mCD1d tetramers and anti-CD3 antibody, were also
analyzed for PD-1 expression by flow cytometry.
Assessment of in vivo T cell proliferation by CFSE dilution
Donor splenocytes were obtained from tandem dimer tomato
(tdT) red fluorescent protein-transgenic mice expressing ovalbu-
min-specific OT-I TCR-transgenes (tdT-Tg/OT-I TCR-Tg
mice), and CD8
+ T cells were isolated using a CD8 negative
selection kit (Miltenyi Biotech, San Diego, CA). After isolation,
CD8
+ T cells were labeled with 10 mM CFSE (Molecular Probes,
Eugene, OR). Recipient human CD1d knock-in mice received
5610
6 labeled cells via the lateral tail vein, and were then
vaccinated s.c. with 5610
6 CFU of glycolipid-modified or
unmodified rBCG-OVA as indicated, or received PBS plus
0.05% tyloxapol as a negative control. Splenocytes were harvested
6 days later, stained with anti-B220-APC and anti-CD8-PerCP,
and analyzed using a LSR-II-yellow flow cytometer (BD Biosci-
ences). CFSE fluorescence of the transferred population was
determined by gating on the B220
negCD8
+ lymphocytes express-
ing tdTomato.
Statistical analysis
All statistical analyses were carried out using non-parametric
tests. A Mann-Whitney test was used for pair-wise comparisons,
and a Kruskal-Wallis test for multiple comparisons. For post-hoc
analysis after Kruskal-Wallis test, we performed a Mann-Whitney
U test using the Bonferroni correction to adjust the probability.
Values of P,0.05 were considered statistically significant. All
statistical tests were done using Prism software (GraphPad).
Supporting Information
Figure S1 Chemical structure of glycolipids used in this
study. The structures of a-C-GC and 7DW8-5 are similar to that
of the parental O-glycoside, a-GC. However, in a-C-GC there is
an a-anomeric carbon-based glycosidic linkage, whereas in
7DW8-5 there is a shorter fatty amide chain terminating in a p-
fluorinated benzene ring.
(TIF)
Figure S2 Representative flow cytometer data to illus-
trate the gating strategies for identifying the AL11
tetramer positive CD8
+ T cell population. Forward (FSC-
A) and side (SSC-A) scatters were used to gate T lymphocyte
population. Dead cells were excluded from Blue Live/Dead
staining followed by exclusion of non-singlet events using forward
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+ T cells were gated from
the CD8
+ B220
neg population and analyzed for AL11 tetramer
staining.
(TIF)
Figure S3 Kinetics of serum cytokine responses to free
glycolipids. IFN-c and IL-4 responses in mice during 48 hour
time period following the intraperitoneal injection of 4 nmoles of
free glycolipids. Control mice received saline injections. Median
values with interquartile ranges are shown for groups of three mice
sampled at each time point.
(TIF)
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